endostatin adenovirus

Gene therapyexperimental

Clinical trial activity

4 trials · 5 clinical orgs · 0 marketing orgs

Phase 1
2
Phase 2
2
Phase 3
0
Phase 4
0

Earliest trial started May 1, 2005 (NCT00262327)

Timeline

2000s

  1. Jan 1, 2005

    Earliest Phase 1 Sponsor(trial)

2010s

  1. Jan 1, 2014

    Earliest Phase 2 Sponsor(trial)

Indications

Mechanism of action

Chemistry & pharmacology

Oral

No

Parenteral

No

Topical

No

Also known as

  • endostatin adenovirus
  • recombinant human endostatin adenovirus

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT07154108Phase 1Sep 1, 2025Sichuan University
NCT03208335Phase 2Jan 1, 2017People's Liberation Army of China
NCT02283489Phase 2Oct 1, 2014Chengdu Shi Endor Biological Engineering Technology Co., Ltd, Sichuan University
NCT00262327Phase 1May 1, 2005Doublle Bioproduct Inc, Sun Yat-Sen University
Showing 4 of 4 trials
Page 1 / 1

Organizations

Research & Development (5)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Sichuan UniversityAcademic/Hospital2122014
Chengdu Shi Endor Biological Engineering Technology Co., LtdGovernment1112014
Doublle Bioproduct IncFor profit1012005
People's Liberation Army of ChinaGovernment1112017
Sun Yat-Sen UniversityAcademic/Hospital1112005
5 organizations
Page 1 / 1